What Is Sematrinity? India's New GLP-1 Breakthrough Explained

Something historic happened in India's pharmaceutical market today. On March 20, 2026, the patent on semaglutide, the active ingredient in Ozempic and Wegovy, expired. More than two dozen Indian companies were preparing to launch over 50 semaglutide brands.

One of the first launches is Sun Pharma's Sematrinity: a once-weekly generic semaglutide injection for type 2 diabetes, announced on March 21, 2026.

What is Sematrinity?

Sematrinity is a generic semaglutide injection developed by Sun Pharma, India's largest pharmaceutical company. It is a GLP-1 receptor agonist: the same class of medication as Ozempic and Wegovy, containing the same active molecule, delivered via a multi-dose pre-filled pen with a dial for setting the dose.

Key details:

• Active ingredient: Semaglutide
• Form: Once-weekly subcutaneous injection (multi-dose prefilled pen)
• Pen strengths: 2 mg/1.5 mL and 4 mg/3 mL
• Indication: Adults with insufficiently controlled type 2 diabetes (adjunct to diet and exercise)
• Launched: March 21, 2026
• Manufacturer: Sun Pharmaceutical Industries Ltd.

Sun Pharma has also launched Noveltreat as a separate brand indicated for chronic weight management in adults, in five strengths from 0.25 mg to 2.4 mg, keeping the two indications distinct.

How does Sematrinity work?

Sematrinity works exactly like branded semaglutide. It mimics the GLP-1 (glucagon-like peptide-1) hormone that your gut naturally releases after eating. This triggers several effects:

• Stimulates insulin release from the pancreas (in a glucose-dependent manner)
• Suppresses glucagon: reducing excess glucose production by the liver
• Slows gastric emptying: food stays in the stomach longer, extending satiety
• Reduces appetite signals in the brain

Together, these mechanisms improve blood sugar control for people with type 2 diabetes and produce meaningful weight loss as a secondary benefit.

What does the clinical evidence say?

Semaglutide's clinical evidence base is among the strongest in modern medicine. The SUSTAIN trial program (for diabetes) and STEP trial program (for obesity) together involved tens of thousands of patients across multiple countries.

Key results from semaglutide trials:

• HbA1c reduction: In the SUSTAIN trials in type 2 diabetes, weekly semaglutide lowered HbA1c by roughly 1.5 percentage points on average
• Weight loss: People with type 2 diabetes on diabetes doses typically lose a few kilograms; the larger average loss of about 15% over 68 weeks (STEP 1) was seen with the 2.4 mg weight-management dose in people without diabetes
• Cardiovascular benefit: In SUSTAIN-6, semaglutide reduced the risk of major cardiovascular events in people with type 2 diabetes at high cardiovascular risk

These results come from studies of the originator semaglutide. Sematrinity is approved by Indian regulators on the basis of the same active ingredient; ask your doctor about the local data supporting the brand you are prescribed.

Launch details: what is available from today

Sun Pharma launched Sematrinity in all strengths on March 21, 2026:

• Pharmacies: Licensed pharmacies, including online pharmacies that verify prescriptions
• Prescription required: Available only with a valid prescription from a registered medical practitioner

Stock can vary by city and pharmacy, so ask your pharmacist.

What does Sematrinity cost?

This is where the patent expiry makes a real difference.

Prices can change, so check the current price with your pharmacy.

With an estimated 101 million people living with diabetes in India (ICMR-INDIAB study, 2023), and almost one in four Indians aged 15 to 49 overweight or obese (NFHS-5), lower-cost semaglutide could meaningfully shift treatment patterns.

Sematrinity vs other generics launching today

Sematrinity is not the only semaglutide generic launching with the patent expiry. Major players include:

• Semaglyn, Mashema and Alterme: Zydus Lifesciences
• Obeda: Dr. Reddy's
• GLIPIQ: Glenmark
• Semasize, Obesema and Hepaglide: Alkem
• Sembolic and Semalix: Torrent
• and many others

Sun Pharma's advantage is brand recognition, distribution scale, and manufacturing quality consistency. For patients choosing between generics, the prescribing physician's recommendation and pharmacy availability will typically guide the decision.

How to use Sematrinity

Sematrinity is self-administered via a prefilled pen injected subcutaneously (under the skin) once weekly, into the abdomen, thigh, or upper arm.

Usual semaglutide titration for type 2 diabetes (follow your doctor's plan):

• Weeks 1–4: 0.25 mg once weekly (a starting dose to reduce stomach side effects)
• From week 5: 0.5 mg
• Any further increase is made by your doctor, at least 4 weeks apart, up to the maximum on the product label
• Weight management at doses up to 2.4 mg uses a different Sun Pharma brand (Noveltreat), not Sematrinity

Never change your dose without your doctor. Start with a consultation with an endocrinologist or diabetologist to confirm appropriate dosing for your situation.

Safety: when to get help

• Seek urgent medical help for severe stomach pain that does not go away (it may spread to your back), signs of a serious allergic reaction, or vomiting so much that you cannot keep fluids down.
• Low blood sugar is more likely if you also take insulin or a sulfonylurea; your doctor may adjust those medicines.
• Report any change in vision, especially if you have diabetic eye disease.
• Do not use semaglutide if you or a family member has had medullary thyroid cancer or you have MEN 2. It is not used in pregnancy.
• Tell your doctor or anaesthetist that you take it before any surgery or sedation.

Tips for best results

• Combine with a balanced, reduced-calorie diet as advised by your doctor or dietitian, and aim for around 150 minutes of physical activity per week
• Source only from licensed pharmacies: counterfeit GLP-1 products are a known risk in India and internationally
• Expect nausea in the first few weeks, this is common and typically fades
• Log your doses and symptoms consistently; it helps you and your doctor spot patterns early

Weight Easy supports semaglutide tracking including generics, and will be updated to include Sematrinity as Indian users adopt it.

Final takeaway

Sematrinity is Sun Pharma's generic semaglutide for type 2 diabetes, launched in India on March 21, 2026, the day after semaglutide's patent expired. Priced well below the originator brand at launch, it brings once-weekly GLP-1 therapy within realistic reach for many more Indian adults with type 2 diabetes. For weight management, Sun Pharma's brand is Noveltreat.

Always consult your healthcare provider before starting any medication.

Consult your healthcare provider before starting any medication.

Sources

• Sun Pharma launch press release for Noveltreat and Sematrinity, March 21, 2026: https://sunpharma.com/wp-content/uploads/2026/03/SEintimationPRforSemaglutide.pdf
• Ozempic India launch and prices (The National, December 12, 2025): https://www.thenationalnews.com/health/2025/12/12/ozempic-india-weight-loss-drug/
• Novo Nordisk India price cut (Business Today, March 31, 2026): https://www.businesstoday.in/amp/industry/pharma/story/novo-further-cuts-semaglutide-prices-as-generics-enter-india-523336-2026-03-31/
• Dr. Reddy's Obeda launch (BioSpectrum India): https://biospectrumindia.com/news/73/27524/dr-reddys-laboratories-announces-launch-of-dcgi-approved-semaglutide-injection-obeda-for-type-2-diabetes.html
• SUSTAIN-6 trial (NEJM): https://www.nejm.org/doi/full/10.1056/NEJMoa1607141
• STEP 1 trial (NEJM): https://www.nejm.org/doi/full/10.1056/NEJMoa2032183
• Ozempic prescribing information: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/209637s025lbl.pdf
• Wegovy prescribing information: https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/215256s011lbl.pdf
• ClinicalTrials.gov: https://clinicaltrials.gov/
• MedlinePlus — semaglutide injection: https://medlineplus.gov/druginfo/meds/a618008.html